BACKGROUND: Pneumonia is a common diagnosis in general practice in the United Kingdom. Previous studies suggest that commonly prescribed drugs in general practice may influence pneumonia mortality. AIM: We investigated whether statins, angiotensin converting enzyme inhibitors (ACEIs), proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H(2)RAs) have an impact on short-term and long-term mortality in pneumonia cases. DESIGN OF STUDY: Population-based cohort study SETTTING: United Kingdom METHODS: Data on 3681 pneumonia cases above the age of 40 years were obtained from a comprehensive database called the health improvement network (THIN) which has computerised medical records from 300 general practice surgeries in the United Kingdom. We used Cox regression for our analyses. RESULTS: Current statin use was associated with a 67% decrease in 30-day mortality (adj. HR: 0.33, 95% CI: 0.19-0.58) and a 55% decrease in long-term mortality (adj. HR: 0.45, 95% CI: 0.32-0.62) over a median follow-up of 2.8 years as compared to no-use. Current ACEI use decreased the 30-day mortality risk by nearly 38% as compared to no-use (adj. HR: 0.62, 95% CI: 0.47-0.82) but was not associated with long-term mortality. No significant impact on mortality was observed for either gastric acid suppressant. CONCLUSION: The use of statins is associated with a lower risk of short- and long-term mortality following pneumonia whereas the use of ACEIs is associated with a decreased mortality risk only in the short-term. Copyright 2009 John Wiley & Sons, Ltd.
BACKGROUND:Pneumonia is a common diagnosis in general practice in the United Kingdom. Previous studies suggest that commonly prescribed drugs in general practice may influence pneumonia mortality. AIM: We investigated whether statins, angiotensin converting enzyme inhibitors (ACEIs), proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H(2)RAs) have an impact on short-term and long-term mortality in pneumonia cases. DESIGN OF STUDY: Population-based cohort study SETTTING: United Kingdom METHODS: Data on 3681 pneumonia cases above the age of 40 years were obtained from a comprehensive database called the health improvement network (THIN) which has computerised medical records from 300 general practice surgeries in the United Kingdom. We used Cox regression for our analyses. RESULTS: Current statin use was associated with a 67% decrease in 30-day mortality (adj. HR: 0.33, 95% CI: 0.19-0.58) and a 55% decrease in long-term mortality (adj. HR: 0.45, 95% CI: 0.32-0.62) over a median follow-up of 2.8 years as compared to no-use. Current ACEI use decreased the 30-day mortality risk by nearly 38% as compared to no-use (adj. HR: 0.62, 95% CI: 0.47-0.82) but was not associated with long-term mortality. No significant impact on mortality was observed for either gastric acid suppressant. CONCLUSION: The use of statins is associated with a lower risk of short- and long-term mortality following pneumonia whereas the use of ACEIs is associated with a decreased mortality risk only in the short-term. Copyright 2009 John Wiley & Sons, Ltd.
Authors: Fiona Havers; Anna M Bramley; Lyn Finelli; Carrie Reed; Wesley H Self; Christopher Trabue; Sherene Fakhran; Robert Balk; D Mark Courtney; Timothy D Girard; Evan J Anderson; Carlos G Grijalva; Kathryn M Edwards; Richard G Wunderink; Seema Jain Journal: Clin Infect Dis Date: 2016-05-10 Impact factor: 9.079
Authors: Timothy L Wiemken; Robert R Kelley; Rafael Fernandez-Botran; William A Mattingly; Forest W Arnold; Stephen P Furmanek; Marcos I Restrepo; James D Chalmers; Paula Peyrani; Rodrigo Cavallazzi; Jose Bordon; Stefano Aliberti; Julio A Ramirez Journal: Univ Louisville J Respir Infect Date: 2017-01-30
Authors: Hieu V Duong; Lauren Nicholas Herrera; Justin Xavier Moore; John Donnelly; Karen E Jacobson; Jestin N Carlson; N Clay Mann; Henry E Wang Journal: Prehosp Emerg Care Date: 2017-09-01 Impact factor: 3.077
Authors: Abdur Rahman Khan; Muhammad Riaz; Aref A Bin Abdulhak; Mohamad A Al-Tannir; Musa A Garbati; Patricia J Erwin; Larry M Baddour; Imad M Tleyjeh Journal: PLoS One Date: 2013-01-07 Impact factor: 3.240